38335-14-7Relevant academic research and scientific papers
Synthesis of Disulfide-Bridged N-Phenyl-N′-(alkyl/aryl/heteroaryl)urea Derivatives and Evaluation of Their Antimicrobial Activities
Dilem Do?an, ?engül,Buran, Sümeyye,G?zde Gündüz, Miyase,?zkul, Ceren,Siva Krishna, Vagolu,Sriram, Dharmarajan
, (2019/11/22)
The discoveryof new antimicrobial agents is extremely needed to overcome multidrug-resistant bacterial and tuberculosis infections. In the present study, eight novel substituted urea derivatives (10a–10h) containing disulfide bond were designed, synthesized and screened for their in vitro antimicrobial activities on standard strains of Gram-positive and Gram-negative bacteria as well as on Mycobacterium tuberculosis. According to the obtained results, antibacterial effects of the compounds were found to be considerably better than their antimycobacterial activities along with their weak cytotoxic effects. Molecular docking studies were performed to gain insights into the antibacterial activity mechanism of the synthesized compounds. The interactions and the orientation of compound 10a (1,1′-((disulfanediylbis(methylene))bis(2,1-phenylene))bis(3-phenylurea)) were found to be highly similar to the original ligand within the binding pocket E. faecalis β-ketoacyl acyl carrier protein synthase III (FabH). Finally, a theoretical study was established to predict the physicochemical properties of the compounds.
Naaladase inhibitors for treating retinal disorders and glaucoma
-
, (2008/06/13)
The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
(E)-3-[[[[6-(2-Carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2- pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: High affinity leukotriene B4 receptor antagonists
Daines,Chambers,Eggleston,Foley,Griswold,Haltiwanger,Jakas,Kingsbury,Martin,Pendrak,Schmidt,Tzimas,Sarau
, p. 3327 - 3336 (2007/10/02)
(E)-3-[[[[6-(2-Carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2- pyridinyl]-methyl]thio]methyl]benzoic acid (11, SB 201993) is a novel, potent LTB4 receptor antagonist. Compound 11 arose from a structure-activity study of a series of trisubstituted pyridines that demonstrated LTB4 receptor antagonist activity. The placement of an additional methylene unit in the sulfur containing chain linking the pyridine and benzoic acid moieties of lead compound 8 (K(i) = 80 nM) resulted in a greater than 10-fold increase in receptor affinity. Additionally, in this new series of compounds, the oxidation state of the sulfur was found to be critical to the activity, i.e., the sulfoxide and sulfone showed substantially lower affinity for the LTB4 receptor. Compound 11 competitively inhibits the binding of [3H]LTB4 to LTB4 receptors on human polymorphonuclear leukocutes with a K(i) of 7.1 nM and blocks both the LTB4-induced calcium mobilization and the LTB4-induced degranulation responses in these cells with IC50 values of 131 and 271 nM, respectively. Compound 11 demonstrated oral LTB4 antagonist activity as well as topical antiinflammatory activity in the mouse.
A new convenient method for preparation of condensed aromatic and heterocyclic thiolactones
Vegh,Morel,Decroix,Zalupsky
, p. 2057 - 2061 (2007/10/02)
Cyclocondensation of the benzylic-type thiols (Ib-VIb) in ortho position on aromatic and heteroaromatic carboxylic acids to form the corresponding thiolactones (Ic-VIc) can be effected with polyphosphate esters (PPE) in organic solvents in 75-90% yields.
